Copeptin and Nonalcoholic Fatty Liver Disease

• ClinicalTrials.gov Identifier: NCT03254563
• Recruitment Status: Recruiting
• First Posted: August 18, 2017
• Last Update Posted: February 10, 2021
• Sponsor: University of Colorado, Denver
• Information provided by (Responsible Party): University of Colorado, Denver

Study Description

Brief Summary:

Copeptin, a surrogate marker for vasopressin, has been found to be elevated in metabolic disorders including obesity and diabetes, which are disorders both associated with nonalcoholic fatty liver disease (NAFLD), and therefore suggest a potential role for vasopressin in the pathogenesis of NAFLD. The investigators intend to investigate if there is an association of vasopressin with the presence and severity of NAFLD.

Condition or disease
NAFLD

Detailed Description:

Participants: As a pilot study, the investigators will recruit 30 obese adults with NAFLD based upon ultrasound echogenicity within 6 months of enrollment, and 30 obese adults without NAFLD based upon ultrasound (US) echogenicity for comparison.

Screening Visit/Study Visit: Patients in the investigator's Obesity clinic will be approached about the study and consented if interested at the screening. Participants will have a chart review for their history and physical Exam and medication review for inclusion and exclusion criteria. Qualified participants will be invited for a screening visit to be scheduled in conjunction with the labs and procedures performed as Standard of Care (SOC) in the obesity clinic. At the screening visit, following consent, participants will have vitals (blood pressure, Body Mass Index (BMI), waist circumference) and a physical examination performed. Participants' Standard of Care (SOC) labs including fasting lipid panel, HbA1c (unless done within last 3 months), comprehensive metabolic panel, titers for hepatitis b and c, and complete blood count will be drawn, along with the following research labs: insulin, glucagon, free fatty acids, adiponectin and a 24-hour urine cortisol collection. Those who have not had an abdominal US will have a SOC US performed to delineate non-NAFLD or NAFLD status. US will not be performed if already done within 6 months of enrollment. All ultrasound studies will be interpreted by one University of Colorado Denver radiologist to categorize the patient as NAFLD or non-NAFLD to limit inter-reader variability. Those with NAFLD present on US will also have a SOC Fibroscan done to assess severity of steatosis (based upon Controlled Attenuation Parameter or CAP Score) and fibrosis (based upon elastography). Given limitations of ultrasound to accurately detect significant steatosis unless >30%, the investigators will in addition perform Fibroscan (all particpants regardless of US) to assess steatosis, so as to confirm if significant steatosis and compare copeptin levels on a continuum of level of steatosis as part of research procedure. Fibroscan can detect steatosis (based upon Controlled Attenuation Parameter or CAP Score) and fibrosis (based upon elastography). FIbroscan with M probe has been found to have AUROC 0.823 for a cutoff of value of 248 dB/m for no steatosis vs steatosis (with other cutoffs at 268 dB/m between S1 and S2-S3 and 280 dB/m between S1-S2 and S3 disease).

Study Design

• Study Type: Observational
• Estimated Enrollment: 60 participants
• Observational Model: Other
• Time Perspective: Cross-Sectional
• Official Title: Copeptin and Nonalcoholic Fatty Liver Disease
• Actual Study Start Date: June 19, 2018
• Estimated Primary Completion Date: June 2021
• Estimated Study Completion Date: June 2021

Groups and Cohorts

Group/Cohort
Obese with NAFLD; Patients who have NAFLD based upon ultrasound
Obese without NAFLD; Patients who do not have NAFLD based upon ultrasound

Outcome Measures

Primary Outcome Measures :

1. Comparision of Copeptin with and without NAFLD [ Time Frame: Within 6 months of documented NAFLD or non-NAFLD and within 1 week of fibroscan ]
   The investigators will compare level of copeptin with the measurement of NAFLD based upon ultrasound and fibroscan.
2. Copeptin and level of steatosis [ Time Frame: Within one week of fibroscan being perfomed ]
   Comparison of CAP score of fibroscan to copeptin levels
3. Copeptin and Liver Elastography [ Time Frame: Within one week of fibroscan being perfomed ]
   Compare Copeptin to liver elastography (kPa)

Secondary Outcome Measures :

1. Insulin Resistance and copeptin [ Time Frame: Same day as these labs after 8 hour fast from food and water. ]
   Changes in insulin, fasting glucose, HOMA-IR, HOMA-B, adiponectin estimated Insulin Compared to copeptin level
2. Copeptin and Lipids [ Time Frame: Same day as these labs after 8 hour fast from food and water. ]
   Compare copeptin level to cholesterol and free fatty acids
3. Copeptin and Liver enzymes [ Time Frame: Same day as these labs after 8 hour fast from food and water. ]
   Compare copeptin and liver enzymes
4. Copeptin and Weight [ Time Frame: Within 1 month of screening visit ]
   Compare Copeptin with BMI
5. Copeptin and Waist Circumference [ Time Frame: Within 1 month of screening visit ]
   Compare copeptin with weight circumference
6. Copeptin and Blood pressure [ Time Frame: Within 1 month of screening visit ]
   Compare copetin with measurements of blood pressure

Biospecimen Retention:   Samples Without DNA

Serum and urine

Eligibility Criteria

• Ages Eligible for Study: 30 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Probability Sample

Study Population

1. Obese adults (BMI 30-40 kg/m2) age 30-75 years with NAFLD based upon ultrasound echogenicity within 6 months of enrollment
2. Obese adults (BMI 30-40 kg/m2) age 30-75 years without NAFLD based upon ultrasound echogenicity within 6 months of enrollment

Criteria

Inclusion Criteria:

1. Patients age 30-75
2. BMI 30-40
3. Presence of fatty liver on ultrasound

Exclusion Criteria:

1. Diabetes mellitus (determined by prior HbA1c, fasting glucose, and/or random glucose in the last three months according to ADA criteria),
2. Medication known to affect insulin sensitivity e.g. metformin, thiazolidinediones, systemic steroids, atypical antipsychotics),
3. Fibrates,
4. eGFR <45 ml/min/1.73m2 by MDRD equation(11),
5. Pregnancy,
6. Breast feeding,
7. Sodium <135 mEq/L,
8. Diabetes insipidus,
9. Liver disease other than NAFLD (including obstructive liver disease),
10. ALT or AST>60 IU/L,
11. Hepatic steatosis on ultrasound for the non-NAFLD group,
12. Congestive heart failure,
13. Patients who consume >20g of ETOH a day,
14. Patients found to have Cushing's disease based upon 24 hour urine results (Urine Free cortisol >2x upper limit of normal).
15. Patient's with pacemakers
16. Off of Coenzyme Q for 6 months.

Contacts and Locations

Contacts

Contact: Thomas Jensen, MD; 7208482650; thomas.jensen@ucdenver.edu

Contact: Kristen Nadeau, MD; (720) 777-6128; Kristen.Nadeau@childrenscolorado.org

Locations

United States, Colorado

University of Colorado; Recruiting

Aurora, Colorado, United States, 80045

Contact: Thomas Jensen, MD 720-848-2650

Contact: Kristen Nadeau, MD 720-777-2855 Kristen.Nadeau@childrenscolorado.org

Sponsors and Collaborators

University of Colorado, Denver

Investigators

• Principal Investigator: Thomas Jensen, MD; University of Colorado, Denver

More Information

• Responsible Party: University of Colorado, Denver
• ClinicalTrials.gov Identifier: NCT03254563
• Other Study ID Numbers: 17-1160
• First Posted: August 18, 2017
• Last Update Posted: February 10, 2021
• Last Verified: February 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Liver Diseases; Fatty Liver; Non-alcoholic Fatty Liver Disease; Digestive System Diseases